ZEISS Medical Technology

What ZEISS Medical Technology does

ZEISS Medical Technology is a segment of the ZEISS Group that develops and manufactures optical and imaging technologies for ophthalmology and microsurgery. The portfolio includes surgical microscopes, femtosecond laser systems (VISUMAX) used for minimally invasive refractive procedures (SMILE), optical biometry systems (IOLMaster), and ultra-widefield retinal imaging systems (CLARUS). The segment operates through Carl Zeiss Meditec AG, a publicly listed subsidiary on the Frankfurt Stock Exchange (ticker: AFX), and serves eye care professionals, hospitals, and microsurgery centers globally. ZEISS Medical Technology builds on the parent ZEISS Group's 175+ year heritage in optics and photonics and is supported by the group's broader R&D investment of approximately EUR 1.7+ billion annually (roughly 15% of group revenue).

The segment generates revenue primarily through direct enterprise sales of hardware-based capital equipment to hospitals, eye clinics, and microsurgery centers, supported by software, service, and consumables. Go-to-market is executed through a global network of over 60 sales and service sites across approximately 50 countries, employing a consultative field-sales model suited to complex medical devices that require clinical evaluation, installation, training, and ongoing service. The Medical Technology segment generated EUR 2.704 billion in fiscal year 2024/25, a 4% year-over-year increase (6% adjusted for currency effects) versus EUR 2.611 billion in fiscal year 2023/24.

The ZEISS Group is wholly owned by the Carl Zeiss Foundation, established in 1889 by Ernst Abbe, one of the oldest company-affiliated foundations in Germany and explicitly prohibited from selling its ZEISS shares. This ownership structure provides long-term orientation and stable funding for R&D, while Carl Zeiss Meditec AG remains publicly traded as the listed medical technology entity. The segment competes across two primary verticals: ophthalmology (cataract, refractive, retinal, and glaucoma diagnostics and treatment) and microsurgery (neurosurgery visualization, oncology, and precision surgical interventions).

Name

ZEISS Medical Technology

Legal name

Carl Zeiss AG

Website

https://zeiss.com

Company type

Private

Founded year

1846

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

ZEISS Medical Technology is a segment of the ZEISS Group that develops optical and imaging systems for ophthalmology and microsurgery, including surgical microscopes, the VISUMAX refractive laser, and the SMILE procedure, sold to hospitals, eye clinics, and surgical centers globally through direct enterprise sales.

Ownership category

akta.pro rank

Product category

Ophthalmic Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Cornea, External Disease & Refractive Surgery (LASIK/PRK) (HLAKAKAF)

akta.pro secondary industry

Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography) (HLAHAJAB)

Keywords

• Ophthalmic surgical equipment
• Medical imaging devices
• Refractive surgery systems
• Surgical microscopy solutions
• Diagnostic imaging systems

Headquarters

HQ city

Oberkochen

HQ country

Germany

HQ region

Europe

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Medical Technology Segment Revenue: ZEISS Medical Technology generates revenue through the sale of medical devices and solutions for ophthalmology and microsurgery. Revenue is reported as a segment of the ZEISS Group, with the segment achieving EUR 2.704 billion in fiscal year 2024/25, a 4% year-over-year increase (6% adjusted for currency effects). The segment's revenue model is primarily hardware-driven with associated software, service, and consumables.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

ZEISS Medical Technology develops, manufactures, and sells optical, laser, and imaging medical devices for ophthalmology and microsurgery. Core offerings include the VISUMAX femtosecond laser system that enables the SMILE minimally invasive refractive surgery procedure, surgical microscopes for neurosurgery and oncology, and AI-integrated diagnostic imaging systems such as the IOLMaster optical biometry platform and CLARUS ultra-widefield retinal imager. The segment sells these products primarily through enterprise field sales to hospitals, eye clinics, and microsurgery centers worldwide.

Product overview

ZEISS Medical Technology is a segment of the ZEISS Group focused on ophthalmology and microsurgery solutions. The portfolio includes VISUMAX laser systems for refractive surgery and SMILE procedures, which work together to enable minimally invasive vision correction treatments. The segment aims to shape medical progress in ophthalmology and microsurgery, helping medical professionals enhance patients' quality of life.

Differentiator

Problem solved

Functional benefit

Brands

• ZEISS SMILE: Minimally invasive lenticule extraction technology for vision correction using VISUMAX laser system.
• ZEISS VISUMAX
• ZEISS IOLMaster
• ZEISS CLARUS

Products and services

• VISUMAX
• SMILE
• IOLMaster

Quantifiable outcome

• Medical Technology segment revenue of EUR 2.704 billion in FY 2024/25, growing 4% (6% currency-adjusted) year-over-year
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

One partnership is on record.

• LG ChemstrategicStrategic or Co-development Partner · 29 October 2025ZEISS and LG Chem established a strategic partnership to supply photopolymer films for automotive holographic windshield displays, with production targeted for 2029. The alliance aims to strengthen supply chain resilience and support growth in holography and optical technologies in mobility and other sectors. This partnership extends ZEISS's optical technology into the automotive augmented reality display market.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• HOYA Corporation: HOYA Vision Care is a major competitor in intraocular lenses and ophthalmic optics, with broader operations in electronics and imaging. Its IOL business is directly comparable to ZEISS Medical Technology's cataract surgery ecosystem.
• Olympus Corporation: Olympus competes with ZEISS Medical Technology in surgical visualization and microscopes for microsurgery and is a broader medtech incumbent with deep hospital channel relationships that overlap with ZEISS's microsurgery centers.
• Leica Microsystems (Danaher): Leica Microsystems, owned by Danaher, competes with ZEISS Medical Technology in surgical microscopes for neurosurgery and oncology. It is part of a much larger life sciences and diagnostics platform, giving it broader resources than ZEISS's standalone microsurgery offering.

Emerging players

• STAAR Surgical: STAAR Surgical specializes in Implantable Collamer Lenses (ICL) for refractive vision correction, representing an alternative to ZEISS's SMILE/VISUMAX-based corneal refractive surgery. It is a more focused, smaller competitor addressing the same underlying demand for premium vision correction.

Direct peers

• Alcon: Alcon is the largest pure-play ophthalmology company globally, competing head-to-head with ZEISS Medical Technology across cataract surgical devices, refractive surgery lasers (e.g., WaveLight), and intraocular lenses. It is the most direct competitor in premium ophthalmic surgical platforms.
• Heidelberg Engineering: Heidelberg Engineering specializes in OCT, confocal microscopy, and retinal imaging systems, competing with ZEISS Medical Technology's OCT and ultra-widefield retinal imaging products in specialty ophthalmology practices.
• Nidek: Nidek is a Japanese ophthalmic equipment manufacturer offering refractive surgery lasers, diagnostic devices, and surgical systems, with particular strength in refractive and cataract surgery markets that overlap with ZEISS Medical Technology's VISUMAX portfolio.
• Topcon Corporation: Topcon is a leading Japanese manufacturer of ophthalmic diagnostic equipment (OCT, fundus cameras, refractors) and surgical solutions, competing directly with ZEISS's diagnostic imaging portfolio including CLARUS and IOLMaster-class products.
• Johnson & Johnson Vision: Johnson & Johnson Vision (part of J&J MedTech) competes directly with ZEISS Medical Technology across cataract surgery, refractive surgery (including its LASIK platform), and contact lens/ocular surface products, with comparable global commercial scale.
• Bausch + Lomb: Bausch + Lomb is a major competitor in cataract surgery equipment, intraocular lenses, and ophthalmic surgical instrumentation, with global reach that overlaps with ZEISS Medical Technology's installed base in eye clinics and hospitals.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/zeiss_group
• YouTubeyoutube.com/user/ZEISSGroup
• Facebookfacebook.com/zeissgroup
• LinkedInlinkedin.com/company/carl-zeiss-meditec
• Instagraminstagram.com/zeissgroup

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ZEISS Medical Technology